GHK-Cu, NAD, and ipamorelin for weight loss: what the evidence says
Quick answer
The video promotes three multi-peptide stacks combining growth hormone secretagogues, a likely GLP-1 receptor agonist, mitochondrial compounds, and telomere-targeting peptides for body recomposition, cosmetic, and longevity outcomes. Several compounds mentioned (BPC-157, epithalon, SS-31) lack FDA approval and have limited or no randomized controlled human trial data supporting the specific claims made. The commercial call-to-action asking viewers to DM for a personalized stack raises regulatory concerns about soliciting patients for unapproved therapies via social media.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @joinmomentumhealth actually say?
A practitioner from Maryland Integrative Medicine laid out three peptide stacks on TikTok, each bundling multiple compounds for a specific goal. The claims moved fast and stayed vague in ways that matter clinically.
Stack one pairs CJC-1295 and ipamorelin with "brettitrutide" (almost certainly semaglutide or tirzepatide, though the mispronunciation makes it impossible to confirm) and NAD+ for "body recomposition." Stack two combines GHK-Cu, TB-500, and BPC-157 for skin, hair, and "glow." Stack three layers NAD+, SS-31, 5-amino-1MQ (likely what "5-MUS" refers to), thymosin alpha-1, and epithalon for "immune and longevity" benefits, including the specific claim that epithalon "lengthens your telomeres" to extend healthspan and lifespan. The video closes with a pitch to DM for a personalized stack recommendation, which is a commercial call-to-action dressed as clinical guidance.
Does the science back this up?
Some of these compounds have real, if limited, research behind them. Others are being sold on a handful of animal studies and a lot of optimism. The stack framing itself is the biggest scientific problem.
CJC-1295 and ipamorelin do stimulate growth hormone release. A 2006 study by Ionescu and Frohman in the Journal of Clinical Endocrinology and Metabolism confirmed CJC-1295 raises IGF-1 levels in healthy adults. Ipamorelin's human data is thinner but the mechanism is plausible. GHK-Cu has legitimate collagen-stimulating data, primarily in vitro, with Pickart and Margolina (2018, Symmetry) summarizing the preclinical case. BPC-157 and TB-500 have animal healing data but essentially no randomized controlled trials in humans. SS-31 (elamipretide) has some mitochondrial data in heart failure contexts, not in healthy adults seeking longevity. Epithalon's telomere claims come almost entirely from Russian lab research, much of it unpublished in peer-reviewed Western journals. "Lengthens your telomeres" stated as fact is a significant overreach.
What did they get wrong (or right)?
Credit where it is due: the GHK-Cu collagen claim is reasonably supported, and combining a GHRH analog with a ghrelin mimetic like CJC-1295 and ipamorelin is a clinically rational pairing. That part isn't wild.
Here is what they got wrong. First, calling NAD+ a metabolism booster in this context implies a fat-loss effect that the human data does not support. Yoshino et al. (2021, Science) found NMN supplementation had no effect on body composition in postmenopausal women. Second, the mispronounced "brettitrutide" appears to be a GLP-1 receptor agonist being bundled with growth hormone secretagogues without any discussion of cardiovascular risk, pancreatitis history, or contraindications. Stacking a GLP-1 agent with GH-stimulating peptides carries real interaction questions that a 60-second TikTok cannot responsibly address. Third, the epithalon claim that it extends lifespan by lengthening telomeres is stated as established fact. It is not. The evidence is preliminary, largely from one research group, and has not been replicated in large human trials. Presenting it as something you can "implement today" is misleading.
What should you actually know?
Peptide therapy is a legitimate and evolving area of medicine. The problem is that TikTok is not a clinical setting, and a stack recommendation delivered via DM is not a medical evaluation.
Several of these compounds, including BPC-157 and epithalon, are not FDA-approved for any indication. Others like thymosin alpha-1 are approved in some countries but not the US. Compounded versions of these peptides vary in purity and concentration in ways that matter for safety. The FDA issued warning letters about compounded BPC-157 in 2024. If you are genuinely interested in peptide therapy, the entry point should be a full lab panel and a provider who will tell you what they do not know, not just what they can sell you. Anyone offering a personalized peptide stack via DM, without reviewing your bloodwork, medication list, and health history, is skipping steps that exist for your safety.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GHK-Cu, NAD, and ipamorelin for weight loss: what the evidence says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Supports SELECT-context pages where semaglutide claims touch long-term weight change and cardiovascular-risk populations.
PubMed
Semaglutide for cardiovascular event reduction in people with overweight or obesity
Baseline SELECT source for cardiovascular-outcomes framing in people with overweight or obesity.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
GHK-Cu, NAD, and ipamorelin for weight loss: what the evidence says should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this ipamorelin video claims cluster
Best for searchers comparing ipamorelin claims with CJC-1295, sermorelin, and growth-hormone peptide evidence.
Claim verdict
The useful answer behind this video
Claim being checked
The video promotes three multi-peptide stacks combining growth hormone secretagogues, a likely GLP-1 receptor agonist, mitochondrial compounds, and telomere-targeting peptides for body recomposition, cosmetic, and longevity outcomes.
FormBlends verdict
The video promotes three multi-peptide stacks combining growth hormone secretagogues, a likely GLP-1 receptor agonist, mitochondrial compounds, and telomere-targeting peptides for body recomposition, cosmetic, and longevity outcomes. Several compounds mentioned (BPC-157, epithalon, SS-31) lack FDA approval and have limited or no randomized controlled human trial data supporting the specific claims made. The commercial call-to-action asking viewers to DM for a personalized stack raises regulatory concerns about soliciting patients for unapproved therapies via social media.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video promotes three multi-peptide stacks combining growth hormone secretagogues, a likely GLP-1 receptor agonist, mitochondrial compounds, and telomere-targeting peptides for body recomposition, cosmetic, and longevity outcomes. Several compounds mentioned (BPC-157, epithalon, SS-31) lack FDA approval and have limited or no randomized controlled human trial data supporting the specific claims made. The commercial call-to-action asking viewers to DM for a personalized stack raises regulatory concerns about soliciting patients for unapproved therapies via social media.
- CJC-1295 raised IGF-1 in a 2006 JCEM human trial, giving the growth hormone secretagogue stack a plausible mechanism, but long-term body recomposition data in non-deficient adults is limited.
- A 2021 Science study (Yoshino et al.) found NMN supplementation had no effect on body composition in humans, weakening the claim that NAD+ drives fat loss or metabolic improvement in a weight loss stack.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- CJC-1295 raised IGF-1 in a 2006 JCEM human trial, giving the growth hormone secretagogue stack a plausible mechanism, but long-term body recomposition data in non-deficient adults is limited.
- A 2021 Science study (Yoshino et al.) found NMN supplementation had no effect on body composition in humans, weakening the claim that NAD+ drives fat loss or metabolic improvement in a weight loss stack.
- The FDA issued warning letters in 2024 specifically about compounded BPC-157, meaning one of the three stacks promoted here includes a compound under active regulatory scrutiny.
- Epithalon's lifespan and telomere claims originate almost entirely from a single Russian research group and have not been independently replicated in large peer-reviewed human trials.
- Stacking a probable GLP-1 receptor agonist with growth hormone secretagogues raises unanswered interaction questions around cardiovascular risk and glucose metabolism that a 60-second video cannot address.
- GHK-Cu has the strongest evidence base of any compound mentioned, with multiple preclinical studies supporting collagen stimulation, though most human data is from topical rather than systemic use.
- A DM-based stack recommendation without bloodwork, a full medication review, and a documented clinical relationship does not meet the standard of care for prescribing any of these compounds.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
EVAN TAXIN PA C · TikTok creator
7.4K views on this video
#ghkcu #NAD #ipamorelin #peptide #waightloss
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by EVAN TAXIN PA C, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.